Regional analysis highlights North America as the dominant market, maintaining over three-quarters of the global revenue share in 2024, driven by the high prevalence of diabetes and obesity, favorable reimbursement policies, and early adoption of innovative therapies (Figure 3)
In DELIGHT, the combination of saxagliptin and dapagliflozin showed potentially additive but marginal albuminuria-lowering effects in T2D subjects (Pollock et al., 2019)
Our dietitians can help you explore the pros and cons of medication and lifestyle change while honoring your lived experiences
Additionally, patients reported a reduced desire to drink alcohol
Steady-state blood levels require approximately 5 to 6 weeks of daily dosing to establish
A dual-action GLP-1/GIP program for patients whose clinician recommends a two-pathway approach